Table 1.
Study population.
| Patients (n = 1305) | ||
| Age, years | 68.1 10 | |
| Female, no. (%) | 354 (27.1) | |
| BMI, Kg/ | 27.8 4 | |
| Clinical history, no. (%) | ||
| Hypertension | 1001 (76.7) | |
| Hyperlipidaemia | 886 (68.6) | |
| Current smoking | 239 (18.3) | |
| Diabetes mellitus | 324 (24.8) | |
| Prior IHD | 472 (36.2) | |
| Prior MI | 320 (24.5) | |
| Prior PCI | 422 (32.3) | |
| Prior CVA | 60 (4.6) | |
| Peripheral artery disease | 357 (27.4) | |
| COPD | 71 (5.4) | |
| CKD | 332 (25.4) | |
| Clinical presentation | ||
| ACS, no. (%) | 650 (49.8) | |
| STEMI | 169 (12.9) | |
| NSTEMI | 465 (35.6) | |
| UA | 16 (1.2) | |
| CCS, no. (%) | 655 (50.2) | |
| Stress test done, no. (%) | 248 (43.9) | |
| Imaging stress test, no. (%) | 88 (35.5) | |
| Positive stress test, no. (%) | 226 (91.1) | |
| LVEF, % | 53.2 9 | |
| LVEF 40%, no. (%) | 180 (13.8) | |
| Multivessel disease, no. (%) | 899 (68.9) | |
| Multivessel revascularization, no. (%) | 354 (27.1) | |
| Discharge medication, no. (%) | ||
| Aspirin | 1280 (98.1) | |
| P2Y12 inhibitors | 1243 (95.2) | |
| Oral anticoagulants | 20 (1.5) | |
| ACE inhibitors or ARB | 1191 (91.2) | |
| Beta blockers | 1128 (86.4) | |
| Statin | 1189 (91.1) | |
| high-dose statin | 892 (75.0) | |
| Ezetimibe | 203 (15.5) | |
BMI, body mass index; IHD, ischemic heart disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; ACS, acute coronary syndrome; STEMI, ST-segment elevation MI; NSTEMI, non-ST-segment elevation MI; UA, unstable angina; CCS, chronic coronary syndrome; LVEF, left ventricular ejection fraction; ACE, angiotensin converting enzyme; ARB, angiotensin 2 receptor blocker.